Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of an outpatient neurostimulation treatment session, reflecting HOPE Therapeutics’ use of Zeta Surgical’s FDA-cleared TMS navigation system and the growing role of AI-guided precision psychiatry in treatment-resistant depression care.
Pharma & Biotech

Why HOPE Therapeutics’ first Zeta-guided TMS patients matter for psychiatry care

NRx’s HOPE Therapeutics begins Zeta-guided TMS treatments, bringing AI-powered image guidance into outpatient depression care workflows.

Read More
Pharma & Biotech

Does the FDA’s KOURAGE response restore confidence in CalciMedica’s CRAC platform?

CalciMedica can continue developing Auxora after the FDA reviewed KOURAGE safety data without imposing a clinical hold, but a large financing, major potential dilution and a strategic shift toward pulmonary hypertension redefine the CALC investment case.

Read More
Pharma & Biotech

Can TScan’s TSC-101 Phase 1 data justify a pivotal leap as TCRX stock falls?

TSC-101 produced rapid donor chimerism with a commercial-ready manufacturing process, but TScan must still prove that the cellular therapy prevents post-transplant relapse.

Read More
Representative image of a dementia care consultation, reflecting Cognition Therapeutics’ zervimesine development path for dementia with Lewy bodies psychosis and the search for new treatment options for hallucinations and delusions in DLB.
Pharma & Biotech

Could zervimesine become the first approved treatment for dementia with Lewy bodies psychosis?

Cognition Therapeutics’ FDA alignment gives zervimesine a clearer pivotal path in dementia with Lewy bodies psychosis, a high-need disorder with no approved therapy

Read More
Pharma & Biotech

Could Absci’s ABS-201 open a new biologic pathway for androgenetic alopecia treatment?

Absci’s interim ABS-201 data strengthen the early case for a long-acting PRLR antibody in androgenetic alopecia and AI-designed biologics.

Read More
Representative image: An oncology specialist reviews lung scans and clinical trial data as Pfizer’s sigvotatug vedotin Phase 3 survival miss shifts attention to second-line patients, biomarker strategy and first-line combinations.
Pharma & Biotech

Sigvotatug vedotin Phase 3 miss tests Pfizer’s case for integrin beta-6 targeted ADCs

Discover why Pfizer’s sigvotatug vedotin Phase 3 miss shifts attention to second-line patients, biomarkers and first-line combinations.

Read More
A clinician monitors a supervised treatment session as Definium Therapeutics advances DT120, a single-dose investigational therapy for major depressive disorder, following positive Phase 3 results. Representative image.
Pharma & Biotech

Can Definium turn a 50% stock surge into an FDA path for single-dose depression therapy?

DT120 produced a striking Phase 3 antidepressant effect after one supervised dose, but confirmation, functional unblinding, controlled-substance rules and treatment-site economics remain decisive.

Read More
Representative image: Antengene’s ATG-106 licensing deal highlights growing biotech interest in CDH6 x CD3 T cell engagers for solid tumor immunotherapy.
Pharma & Biotech

Antengene, K2 Therapeutics deal signals fresh momentum for solid tumor TCEs

Find out how Antengene’s ATG-106 licensing deal could shape the next phase of solid tumor T cell engager development.

Read More
Representative image: AI-powered drug discovery research lab illustrating Insilico Medicine and SK Biopharmaceuticals’ $2.5 billion CNS neuroimmune drug development pact.
Pharma & Biotech

Why Insilico’s $2.5bn SK Biopharmaceuticals deal could reshape AI drug discovery

Find out how Insilico and SK Biopharmaceuticals are using AI to target neuroimmune CNS disorders in a $2.5B drug discovery pact.

Read More
Pharma & Biotech

Why Praxis’ latest FDA win could matter far beyond one genetic epilepsy program

Find out how Praxis’ FDA Breakthrough Therapy Designation for elsunersen could reshape SCN2A-DEE epilepsy treatment and ASO development.

Read More